Levamisole


w51



General information:


Withdrawn ID: w51
Canonical SMILES:
Standard InChI:
Standard InChIKey:
ATC class(es): P02CE01
Molecular Formula: C11H12N2S
Molweight: 204.291



Withdrawal information:


Withdrawn due to drug safety reasons:Yes
First approved: 1990
First withdrawn: 1999
Last withdrawn: 1999
Reference: https://www.ncbi.nlm.nih.gov/pubmed/7091125



Side-effects:

Total reported cases (submitted by medical professionals) with Levamisole as primary suspect: 11


Reported final outcomes:
Hospitalization (initial or prolonged): 5
Congenital anomaly: 4
Death: 3
Intervention required to prevent permanent impairment/damage: 1
Life-Threatening condition: 1
Disability: 1


Reported side-effects:

Side-effect Case number
PYREXIA4
DRUG EXPOSURE DURING PREGNANCY3
AGRANULOCYTOSIS3
TOXICITY TO VARIOUS AGENTS3
SYNDACTYLY3
SPINA BIFIDA3
CRYPTORCHISM3
ACCIDENTAL EXPOSURE2
CONGENITAL GENITAL MALFORMATION MALE2
RASH2
ANTIPHOSPHOLIPID ANTIBODIES POSITIVE2
BLOOD ALBUMIN DECREASED1
BLOOD BILIRUBIN INCREASED1
CANDIDIASIS1
CELLULITIS1
Completed suicide1
ARTHRALGIA1
DRUG ADMINISTRATION ERROR1
MENTAL STATUS CHANGES1
ELECTROCARDIOGRAM QT PROLONGED1
INTERNATIONAL NORMALISED RATIO INCREASED1
JOINT EFFUSION1
LEUKOENCEPHALOPATHY1
Leukopenia1
WHITE BLOOD CELL COUNT DECREASED1
NEUTROPENIA1
OFF LABEL USE1
Oral infection1
Pain1
PERITONSILLAR ABSCESS1
PLATELET COUNT DECREASED1
PNEUMONIA1
RENAL FAILURE ACUTE1
SINUS TACHYCARDIA1
Skin graft1
Vasculitis1
VENTRICULAR FIBRILLATION1





Toxicity information:

Toxicity class: 3
Toxicity type: hematological
LD50: 138 mg/kg



External links:

ChEBML: CHEMBL1454
DrugBank: DB00848